Literature DB >> 17957565

A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography.

Alex R Hobson1, Graham W Petley, Keith D Dawkins, Nick Curzen.   

Abstract

BACKGROUND: A rapid, reliable, point of care test reflecting patient specific responses to antiplatelet therapy would be of great clinical value in percutaneous coronary intervention (PCI). The aim of this study was to establish whether modified thrombelastography (TEG) can be employed as a 15 minute test of individual patient responses to aspirin and clopidogrel using a novel parameter, percentage clotting inhibition (%CIn). METHODS AND
RESULTS: Thirty healthy volunteers and 10 patients undergoing elective PCI were recruited into four groups: 10 volunteers received a single 300 mg dose of aspirin [A1]: 10 volunteers received aspirin 75 mg daily for 7 days [A2]: 10 volunteers received a 600 mg dose of clopidogrel [C1]: 10 patients received a 600 mg loading dose of clopidogrel prior to elective PCI [C2]. In all cases the area under the clotting response curve was measured at 15 minutes (AUC15) and used to calculate a novel parameter, percentage clotting inhibition (%CIn). Large differences were demonstrated in both aspirin and clopidogrel groups in response to therapy as assessed by both the area under the curve at 15 minutes and %CIn. Furthermore, the technique demonstrated important heterogeneity of time-dependent responses between individuals.
CONCLUSION: Modified TEG, employing AUC15 and %CIn, is a promising tool for assessing responses to aspirin and clopidogrel. Further data are now required to assess the potential of this test to optimise individual therapy in PCI patients in order to detect and treat those patients with relative hypo-responsiveness to anti-platelet drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17957565     DOI: 10.1080/09537100701329162

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  13 in total

Review 1.  Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.

Authors:  Nalyaka Sambu; Nick Curzen
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 2.  Monitoring aspirin and clopidogrel response: testing controversies and recommendations.

Authors:  Athanasios Karathanos; Tobias Geisler
Journal:  Mol Diagn Ther       Date:  2013-06       Impact factor: 4.074

3.  Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.

Authors:  Xiao-Fang Tang; Jing Wang; Jia-Hui Zhang; Xian-Min Meng; Bo Xu; Shu-Bin Qiao; Yong-Jian Wu; Jue Chen; Yuan Wu; Ji-Lin Chen; Run-Lin Gao; Jin-Qing Yuan; Yue-Jin Yang
Journal:  Eur J Clin Pharmacol       Date:  2012-11-14       Impact factor: 2.953

4.  Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China.

Authors:  Hui-Hui Lv; Shuai Wu; Xu Liu; Xiao-Li Yang; Jian-Feng Xu; Yang-Tai Guan; Qiang Dong; S Lilly Zheng; Jian-Ming Jiang; Shi-Xu Li; Zheng Luo; Li Li; Li-Xian An; Yan Han
Journal:  Neurol Sci       Date:  2015-10-31       Impact factor: 3.307

5.  The Potential Value of Near Patient Platelet Function Testing in PCI: Randomised Comparison of 600 mg versus 900 mg Clopidogrel Loading Doses.

Authors:  Alex R Hobson; Zeshan Qureshi; Phil Banks; Nicholas Curzen
Journal:  Thrombosis       Date:  2009-10-20

6.  Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients.

Authors:  Dan-Dan Li; Xu-Yun Wang; Shao-Zhi Xi; Jia Liu; Liu-An Qin; Jing Jing; Tong Yin; Yun-Dai Chen
Journal:  J Geriatr Cardiol       Date:  2016-05       Impact factor: 3.327

7.  Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography.

Authors:  Bartosz Olechowski; Alexander Ashby; Nalyaka Sambu; Michael Mahmoudi; Nick Curzen
Journal:  Case Rep Med       Date:  2016-10-09

8.  Impact of Proton-pump Inhibitors on the Pharmacodynamic Effect and Clinical Outcomes in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: A Propensity Score Analysis.

Authors:  Pei Zhu; Zhan Gao; Xiao-Fang Tang; Jing-Jing Xu; Yin Zhang; Li-Jian Gao; Jue Chen; Shu-Bin Qiao; Yue-Jin Yang; Run-Lin Gao; Bo Xu; Jin-Qing Yuan
Journal:  Chin Med J (Engl)       Date:  2017-12-20       Impact factor: 2.628

9.  Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy.

Authors:  Alex R Hobson; Graham Petley; Geraint Morton; Keith D Dawkins; Nick P Curzen
Journal:  Thromb J       Date:  2008-02-29

10.  Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel.

Authors:  Xiao-Fang Tang; Ya-Ling Han; Jia-Hui Zhang; Jing Wang; Yin Zhang; Bo Xu; Zhan Gao; Shu-Bin Qiao; Jue Chen; Yuan Wu; Ji-Lin Chen; Run-Lin Gao; Yue-Jin Yang; Jin-Qing Yuan
Journal:  Chin Med J (Engl)       Date:  2015-03-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.